• Final Results of a Pilot, 48-Week Study of Amprenavir/Abacavir/Lamivudine (APV/ABC/3TC) in ART-Naive Subjects with HIV-1 Infection (COL30309) (Poster 696)
  Authored by M. Dube, Indiana University, Indianapolis, IN; J. Hernandez, GlaxoSmithKline, Research Triangle Park, NC; H. Edmondson-Melancon, University of Southern CA, Los Angeles, CA; J.W. Fleming, T. Cates, GlaxoSmithKline, Research Triangle Park, NC; F. Sattler, University of Southern CA, Los Angeles, CA; V. Williams, D. Goodwin, GlaxoSmithKline, Research Triangle Park, NC

This is a good study of an AZT-less regimen. The combination of ABC and 3TC for the nucleosides is combined with amprenavir for the protease inhibitor. This could also be a regimen that is very unlikely to cause lipdystrophy or mitochondrial toxicity. Only one patient had the classic abacavir hypersensitivity reaction. Patients were naive to antiretrovirals and there was a good drop in HIV viral load and a rise of 170 in CD4 cells over 48 weeks. Basically, this regimen is as good as any NRTI/PI regimen with 69% of patients having <400 copies at 48 weeks. According to the authors, APV/RTV trials are underway to make this an easier-to-take regimen.